Literature DB >> 12392157

Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.

See-Tarn Woon1, Bruce C Baguley, Brian D Palmer, John D Fraser, Lai-Ming Ching.   

Abstract

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a new anticancer drug synthesized in this laboratory and currently in clinical trial, induces tumor vascular damage in vivo that is mediated primarily by cytokine synthesis by host cells. Although its pharmacology and antitumor activity have been extensively studied, little is known of its action on tumor cell lines. We measured [3H]DMXAA uptake in the Raji, Daudi, Jurkat, ECV304, NZM12, HL60, and K562 human tumor lines using velocity centrifugation through silicon oil layers, and also measured NF-kappaB activation by electrophoretic mobility shift assays. All lines accumulated [3H]DMXAA, and uptake by ECV304 cells was rapid, pH dependent (greater uptake at pH 6.5), similar at 4 degrees C and 37 degrees C, and unaffected by the addition of 5 mM sodium azide. The uptake ratio was 4.5-fold at a low drug concentration (4 microM) and decreased significantly (P < 0.01) to 4.0 as the external drug concentration was increased to 0.7 mM, providing evidence of saturability. [3H]DMXAA interacted weakly with isolated cytoplasmic proteins, as measured by equilibrium dialysis, providing a basis for the observed cellular uptake. Uptake was slightly reduced by addition of a less potent analogue, flavone acetic acid, or of an inactive analogue, 8-methylxanthenone-4-acetic acid, suggesting competition for binding sites. The Raji, Daudi, Jurkat. and ECV304 lines showed evidence of activation of the NF-kappaB transcription factor in response to DMXAA, but the identity of the NF-kappaB subunits translocated to the nucleus varied according to the line. The results are consistent with the hypothesis that DMXAA is taken up rapidly into cells by passive diffusion and binds to cellular proteins. The observed activation of NF-kappaB in some lines suggests that the effects of DMXAA on tumor cells, as well as host cells, must be considered in understanding its antitumoraction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392157

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  5 in total

1.  Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).

Authors:  Guanjun Cheng; Jing Sun; Zvi G Fridlender; Liang-Chuan S Wang; Lai-Ming Ching; Steven M Albelda
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

2.  Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.

Authors:  Romy Brauer; Liang-Chuan S Wang; See-Tarn Woon; David J A Bridewell; Kimiora Henare; Dieter Malinger; Brian D Palmer; Stefanie N Vogel; Claudine Kieda; Sofian M Tijono; Lai-Ming Ching
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

3.  Anticancer flavonoids are mouse-selective STING agonists.

Authors:  Sujeong Kim; Lingyin Li; Zoltan Maliga; Qian Yin; Hao Wu; Timothy J Mitchison
Journal:  ACS Chem Biol       Date:  2013-05-23       Impact factor: 5.100

Review 4.  cGAS-STING pathway in cancer biotherapy.

Authors:  Yang Wang; Jingwen Luo; Aqu Alu; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  Mol Cancer       Date:  2020-09-04       Impact factor: 27.401

Review 5.  Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy.

Authors:  Kewang Luo; Ning Li; Wei Ye; Hanchao Gao; Xinle Luo; Baohui Cheng
Journal:  Molecules       Date:  2022-07-20       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.